# ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST)

> **NCT00041509** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 343 (actual)

## Conditions studied

- Arthroplasty

## Interventions

- **DRUG:** SB-424323
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00041509
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2003-05
- **Final completion:** 2003-05
- **Target enrollment:** 343 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00041509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00041509, "ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00041509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*